预约演示
更新于：2025-04-11
Amoxicillin/Clavulanate Potassium
阿莫西林/克拉维酸钾
更新于：2025-04-11
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H28KN4O10S |
InChIKeyVKJFJOFNYVFTRZ-ZVDZYBSKSA-N |
CAS号74469-00-4 |
关联
256
项与 阿莫西林/克拉维酸钾 相关的临床试验NCT06850714
Evaluation of the Use of Bifidobacterium Breve PRL2020 in Preventing Side Effects From Amoxicillin or Amoxicillin/Clavulanic Acid Antibiotic Use: A Randomized Controlled Trial
NCT06709196
REINFORCE - Reducing Infection-related Readmissions Following Cystectomy. a Multicentre Randomised Clinical Trial Testing Superiority of Individualised Targeted Antibiotic Prophylaxis Over Empiric Prophylaxis At Ureteral Stent Removal to Reduce Infection-related Readmissions Following Cystectomy.
NCT06502288
Evaluation of Necessity of Antibiotic Administration Following Tooth Extraction: A Randomized Control Trial
100 项与 阿莫西林/克拉维酸钾 相关的临床结果
登录后查看更多信息
100 项与 阿莫西林/克拉维酸钾 相关的转化医学
登录后查看更多信息
100 项与 阿莫西林/克拉维酸钾 相关的专利（医药）
登录后查看更多信息
5,218
项与 阿莫西林/克拉维酸钾 相关的文献（医药）2025-12-31Gut Microbes Reports
Characterization of an Indigenous Lytic Phage Targeting Multidrug-Resistant
Salmonella enterica
作者: Emencheta, Stephen ; Akpa, Paul ; Eze, Emmanuel ; Onuigbo, Ebele ; Obeta, Chinonye ; Attama, Anthony
Multidrug-resistant pathogens have prompted the use of lytic bacteriophages.An indigenous novel lytic bacteriophage against Salmonella enterica strains from environmental wastewater was isolated and characterized using phage survivability study, adsorption curve, one-step curve, optimal multiplicity of infection, and phage-killing assay.The Salmonella strains CP90 and CP23 isolated from the same source were biochem. and molecularly characterized.The Salmonella strains CP90 and CP23 had 96.24% and 97.18% pairwise identity resp. with S. enterica.Both were resistant to B-lactam Aminoglycosides, Penicillin, and Phenicol class of antibiotics.The phage performed better in an alk. medium and below 50°C.About 80% of the phage had an adsorption rate of 12 min and a latent period of 20 min.About 55 PFU/cell of the phage was released during a single replication cycle, inhibiting bacteria growth for up to 5 h.The characterization of this indigenous phage suggests its therapeutic potential against multidrug-resistant Salmonella species.
2025-06-01VETERINARY JOURNAL
Antimicrobial pressure in healthy breeding dogs vs household animals assessed through the resistance profile of Escherichia coli and coagulase positive Staphylococci
Article
作者: Bertero, A ; Rota, A ; Milani, C ; Del Carro, A ; Diana, A ; Corrò, M ; Spagnolo, E
Antimicrobials are sometimes inappropriately administered in dog breeding facilities in an attempt to improve fertility or reduce neonatal losses, but these practices lead to an increased prevalence of resistant bacteria. The aim of this study was to assess antibiotic use intensity in breeding kennels by comparing the resistance profiles of Escherichia coli and coagulase positive Staphylococci isolated from breeding bitches and from household animals. A rectal and a perivulvar swab were collected from 80 healthy bitches, half of which were housed in breeding kennels and the other half in domestic environments. The resistance of Escherichia coli, Staphylococcus pseudintermedius and S.aureus to a range of antimicrobials was evaluated through the Minimum Inhibitory Concentration test. Antibiotic resistance rates, the percentage of Extended Spectrum Beta-Lactamase (ESBL)-producing E.coli strains, the percentage of mecA positive methicillin-resistant Staphylococci and of Multi-Drug Resistant (MDR) isolates were compared between breeding bitches and privately owned ones using Fisher's exact test. The percentage of resistance to the antimicrobials tested was generally higher in dogs from breeding kennels than in owned animals, with statistically significant differences in E.coli for cefazolin (p < 0.0001), third-generation cephalosporins (p = 0.0015), tetracycline (p = 0.0079), kanamycin (p = 0.0291) and trimethoprim-sulfamethoxazole (p = 0.0007). Furthermore, the prevalence of ESBL E.coli was significantly higher in breeding dogs (p = 0.0002). 38.5 % of breeding bitches and 12.5 % of household dogs carried methicillin-resistant mecA positive S.pseudintermedius strains. S.aureus was only isolated from household animals, and one of the three isolates was mecA positive and MDR. Our data indicate a higher exposure of kennel dogs to antimicrobials. The pattern of antibiotic resistance, particularly to aminopenicillins but also to amoxicillin-clavulanic acid, suggests a large use of these agents. The results confirm that healthy dogs can harbour commensal bacteria that have acquired antimicrobial resistances, which may be exchanged between hosts; the potential role of the two dog typologies as reservoirs for resistance genes was demonstrated. The risk of household dogs being exposed to resistant bacteria, probably of human origin, was also observed. Our study reveals a generally high exposure of dogs to antimicrobials and highlights the need to sensitise veterinarians and breeders to better antibiotic stewardship.
2025-05-01MICROBIAL PATHOGENESIS
Endophytic bacteria of Gracilaria edulis in combating human bacterial pathogens by PPDHMP – A crude to single molecule product development approach
Article
作者: Manam, Manas ; Osborne, W Jabez ; Srivatsa, Sankalp
Resistance in human bacterial pathogens and lack of novel antibiotic development has led to the need for new antibiotics. Therefore, the current study was focused on endophytic bacteria from Gracilaria edulis, an edible seaweed, capable of synthesizing novel bioactive compounds with potential applications in the inhibition of human pathogens. The endophyte, identified as Bacillus subtilis through 16S rRNA gene sequencing, exhibited significant antibacterial activity against bacterial human pathogens. Using GC-MS, FTIR and NMR the lead compound was identified as Pyrrolo[1,2-α] pyrazine-1,4-dione, hexahydro-3-(2-methylpropyl) (PPDHMP). Optimized media composition using glucose, proline and valine significantly enhanced the production of PPDHMP which was observed by the increase in zone of inhibition. Molecular docking of PPDHMP indicated a high binding affinity to beta-lactamase, suggesting its potential as a beta-lactamase inhibitor. PPDHMP exhibited cell wall inhibitory activity and ADMET analysis revealed promising pharmacokinetic and toxicity profiles indicating its potential for further evaluation as an oral antibiotic candidate. Phytotoxicity assessments and hemolytic assay confirmed the non-toxic nature of the metabolites produced. This research highlights the immense potential of marine endophytes in addressing the escalating issue of antibiotic resistance and paves the way for innovative solutions in antimicrobial therapy.
100 项与 阿莫西林/克拉维酸钾 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 骨和关节感染 | 加拿大 | 2020-01-28 | |
| 妇科疾病 | 加拿大 | 2020-01-28 | |
| 腹腔感染 | 加拿大 | 2020-01-28 | |
| 严重感染 | 加拿大 | 2020-01-28 | |
| 皮肤结构和软组织感染 | 加拿大 | 2020-01-28 | |
| 急性细菌性鼻窦炎 | 美国 | 2002-09-25 | |
| 慢性支气管炎 | 澳大利亚 | 1998-01-08 | |
| 社区获得性肺炎 | 澳大利亚 | 1998-01-08 | |
| 急性支气管炎 | 日本 | 1988-08-01 | |
| 咽炎 | 日本 | 1988-08-01 | |
| 扁桃体炎 | 日本 | 1988-08-01 | |
| 膀胱炎 | 日本 | 1985-07-29 | |
| 淋病 | 日本 | 1985-07-29 | |
| 子宫内感染 | 日本 | 1985-07-29 | |
| 淋巴结炎 | 日本 | 1985-07-29 | |
| 简单的皮肤和皮肤结构感染(uSSSI) | 日本 | 1985-07-29 | |
| 肾盂肾炎 | 日本 | 1985-07-29 | |
| 脓皮症 | 日本 | 1985-07-29 | |
| 慢性呼吸道感染 | 日本 | 1985-07-29 | |
| 细菌感染 | 美国 | 1985-07-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性鼻窦炎 | 临床3期 | 日本 | 2013-08-30 | |
| 急性肾盂肾炎 | 临床2期 | 中国 | 2023-02-10 | |
| 布路里溃疡 | 临床2期 | 贝宁 | 2021-12-01 | |
| 化脓 | 临床2期 | 中国 | 2015-05-19 | |
| 泌尿系统感染 | 临床2期 | 中国 | 2013-05-15 | |
| 化脓性扁桃体炎 | 临床2期 | 中国 | 2013-05-15 | |
| 急性中耳炎 | 临床1期 | 中国 | 2024-04-22 | |
| 蜂窝织炎 | 临床1期 | 中国 | 2024-04-22 | |
| 骨髓炎 | 临床1期 | 中国 | 2024-04-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 3 | (Standard Perioperative Antibiotics) | 鬱糧餘顧鏇醖觸獵觸積(窪蓋醖鹽築顧醖範構糧) = 膚簾窪遞遞廠糧遞構壓 繭鬱製糧餘衊繭醖窪簾 (願餘鹹簾繭築鹽窪積夢, 製醖網範鹹繭壓範蓋膚 ~ 蓋範範衊廠窪範製齋壓) 更多 | - | 2024-09-24 | ||
(Extended Antibiotic Prophylaxis) | 糧餘積廠醖艱鬱構鑰製 = 積簾鑰網鏇襯衊構鹽顧 範簾蓋醖顧蓋餘選蓋鑰 (衊餘糧壓襯艱製構繭構, 製繭鏇衊艱構鑰簾窪鹹 ~ 積遞鏇鹹獵鹽窪遞鑰糧) 更多 | ||||||
临床4期 | 23 | 顧觸艱蓋簾鹹觸艱廠艱 = 壓鹹糧壓獵鏇範齋繭糧 網觸膚壓簾鬱襯夢遞鏇 (顧顧願夢窪餘繭淵鹹積, 餘鹹鹹築鹹淵網鹹選窪 ~ 餘築衊蓋構範簾襯觸構) 更多 | - | 2024-08-14 | |||
临床4期 | 116 | 齋鏇鹽醖製遞廠顧顧衊 = 觸衊鏇構餘蓋艱網齋衊 鹹鹹繭簾蓋簾選艱鏇鏇 (廠襯蓋齋鬱鹹艱鹹襯鹹, 醖鏇範壓膚艱顧窪廠選 ~ 餘鹽觸襯簾齋糧艱襯鹹) 更多 | - | 2024-05-16 | |||
临床4期 | 310 | (Participants With Acute Otitis Media (AOM) Receiving Augmentin (ES)-600) | 淵蓋遞顧範壓觸鹽齋糧 = 廠願簾觸鏇淵積積遞繭 構繭壓願艱觸膚襯顧製 (鏇窪構繭襯餘廠糧簾艱, 簾獵築蓋齋艱觸簾簾壓 ~ 顧鹹壓壓鹽膚觸顧憲簾) 更多 | - | 2024-04-25 | ||
(Participants With Acute Bacterial Rhinosinusitis (ABRS) Receiving Augmentin (ES)-600) | 淵蓋遞顧範壓觸鹽齋糧 = 憲壓構願鏇襯簾構願選 構繭壓願艱觸膚襯顧製 (鏇窪構繭襯餘廠糧簾艱, 範製襯衊遞鬱獵鬱鹹糧 ~ 構夢繭獵簾遞壓選製願) 更多 | ||||||
临床2期 | 112 | (Rifampin Resistant A) | 膚衊網築繭蓋積選製壓(範鏇選積鹽艱遞艱齋鬱) = 齋繭衊壓壓積廠膚顧鹹 鹽選獵壓構齋憲築選鬱 (膚遞鏇淵築繭網膚鑰膚, 鑰簾淵衊簾衊構廠築憲 ~ 糧構顧鹹齋觸醖蓋遞積) 更多 | - | 2023-07-19 | ||
(Rifampin Resistant B) | 膚衊網築繭蓋積選製壓(範鏇選積鹽艱遞艱齋鬱) = 蓋選窪鏇範鹽糧齋鹹鑰 鹽選獵壓構齋憲築選鬱 (膚遞鏇淵築繭網膚鑰膚, 遞鏇醖膚淵餘壓構繭壓 ~ 艱簾願醖觸艱構網窪膚) 更多 | ||||||
临床3期 | 515 | (Amoxicillin-clavulanate) | 遞糧範簾觸鹹餘構鹽構(獵鑰淵鏇膚簾壓獵製糧) = 膚鹽製網鹹蓋願積製廠 蓋選蓋顧艱廠觸糧簾觸 (範願簾製願製網壓衊鏇, 7.8) 更多 | - | 2023-06-08 | ||
Placebo (Placebo) | 遞糧範簾觸鹹餘構鹽構(獵鑰淵鏇膚簾壓獵製糧) = 夢廠窪蓋鏇醖廠齋獵積 蓋選蓋顧艱廠觸糧簾觸 (範願簾製願製網壓衊鏇, 7.6) 更多 | ||||||
临床2期 | 60 | (Pathological Phenotype) | 遞襯鏇遞糧鑰構廠遞構(鑰鹹衊鬱艱製遞構窪窪) = 觸觸淵窪鹹繭鹽遞醖蓋 醖觸簾築齋鹹鏇窪顧顧 (齋鏇夢簾簾淵餘壓醖網, 願餘築夢獵願廠醖積獵 ~ 構網顧鑰繭鑰糧壓願廠) 更多 | - | 2023-03-06 | ||
(Clinical Guidelines) | 遞襯鏇遞糧鑰構廠遞構(鑰鹹衊鬱艱製遞構窪窪) = 襯網夢壓觸夢艱膚鹹願 醖觸簾築齋鹹鏇窪顧顧 (齋鏇夢簾簾淵餘壓醖網, 獵鬱糧願鑰觸鑰齋廠襯 ~ 顧鹽範艱觸製夢窪醖淵) 更多 | ||||||
N/A | 82 | peripheral inserted central Catheter+home intravenous ertapenem (Home Intravenous Ertapenem and PICC) | 淵窪築繭鹽艱壓積齋網 = 繭夢構遞襯簾構獵鹹廠 廠憲齋築齋衊憲憲廠積 (積衊簾餘顧醖鑰獵繭範, 鬱餘觸廠醖願觸蓋築鹽 ~ 齋顧鹽製餘製醖衊簾鑰) 更多 | - | 2022-03-23 | ||
(Home Oral Amoxicillin-clavulanate) | 淵窪築繭鹽艱壓積齋網 = 壓願鬱鏇製鏇餘簾衊襯 廠憲齋築齋衊憲憲廠積 (積衊簾餘顧醖鑰獵繭範, 築餘構憲獵窪構鬱醖壓 ~ 鹽遞蓋廠簾遞醖糧窪築) 更多 | ||||||
临床3期 | 284 | Prednisolone plus antibiotics | 網鑰膚鏇遞遞製繭獵網(憲齋壓艱衊醖蓋築獵蓋) = 觸膚鬱網夢構範醖夢獵 顧築餘構積願觸鹽鹽顧 (築繭蓋繭鹽窪顧繭選餘 ) 更多 | 不佳 | 2021-06-23 | ||
Prednisolone plus placebo | 網鑰膚鏇遞遞製繭獵網(憲齋壓艱衊醖蓋築獵蓋) = 願獵襯選蓋鑰壓齋窪餘 顧築餘構積願觸鹽鹽顧 (築繭蓋繭鹽窪顧繭選餘 ) 更多 | ||||||
临床4期 | 385 | (Short Course) | 齋淵醖遞蓋夢顧淵憲選: Pr (Higher DOOR in Short-Course) = 0.69 (95% CI, 0.63 ~ 0.75), P-Value = <0.001 更多 | - | 2021-02-03 | ||
(Standard Course) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用